JP2021521828A5 - - Google Patents
Info
- Publication number
- JP2021521828A5 JP2021521828A5 JP2020559481A JP2020559481A JP2021521828A5 JP 2021521828 A5 JP2021521828 A5 JP 2021521828A5 JP 2020559481 A JP2020559481 A JP 2020559481A JP 2020559481 A JP2020559481 A JP 2020559481A JP 2021521828 A5 JP2021521828 A5 JP 2021521828A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- salt
- hydroxycitric acid
- cultured
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661941P | 2018-04-24 | 2018-04-24 | |
| US62/661,941 | 2018-04-24 | ||
| PCT/US2019/028513 WO2019209715A1 (en) | 2018-04-24 | 2019-04-22 | Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521828A JP2021521828A (ja) | 2021-08-30 |
| JP2021521828A5 true JP2021521828A5 (enExample) | 2022-05-02 |
| JP7342030B2 JP7342030B2 (ja) | 2023-09-11 |
Family
ID=66641471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559481A Active JP7342030B2 (ja) | 2018-04-24 | 2019-04-22 | ヒドロキシクエン酸および／またはその塩を使用してｔ細胞集団を産生する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12415845B2 (enExample) |
| EP (1) | EP3784774B1 (enExample) |
| JP (1) | JP7342030B2 (enExample) |
| CN (2) | CN112262212B (enExample) |
| AU (1) | AU2019260656B2 (enExample) |
| CA (1) | CA3097858A1 (enExample) |
| WO (1) | WO2019209715A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021021349A2 (pt) * | 2019-04-26 | 2022-02-01 | Allogene Therapeutics Inc | Métodos de fabricação de células car t alogênicas |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| EP4178590A4 (en) * | 2020-07-09 | 2024-09-25 | The Board of Trustees of the Leland Stanford Junior University | MULTIPARALLEL ANALYSIS OF T-CELL THERAPIES |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| US7820174B2 (en) | 2006-02-24 | 2010-10-26 | The United States Of America As Represented By The Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| AU2008206442B2 (en) | 2007-01-12 | 2012-10-18 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | gp100-specific T cell receptors and related materials and methods of use |
| WO2010088160A1 (en) | 2009-01-28 | 2010-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| CN103124740B (zh) | 2010-09-21 | 2015-09-02 | 美国卫生和人力服务部 | 抗-ssx-2t细胞受体和相关材料及使用方法 |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| TR201815488T4 (tr) | 2011-04-08 | 2018-11-21 | Health | Anti-epidermal büyüme faktör reseptörü varyant III kimerik antijen reseptörleri ve kanser tedavisi için kullanımı. |
| CA3114877C (en) | 2011-09-15 | 2023-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| IN2014CN02906A (enExample) | 2011-10-20 | 2015-07-03 | Us Health | |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| ES3065694T3 (en) | 2012-04-11 | 2026-05-07 | Us Health | Chimeric antigen receptors targeting b-cell maturation antigen |
| CN104507963B (zh) | 2012-05-22 | 2017-12-15 | 美国卫生和人力服务部 | 鼠抗‑ny‑eso‑1 t细胞受体 |
| DK2895509T3 (da) | 2012-09-14 | 2020-03-09 | Us Health | T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3 |
| RU2658485C2 (ru) | 2012-10-24 | 2018-06-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы м971 |
| US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| CN110511960B (zh) | 2013-07-15 | 2023-05-23 | 美国卫生和人力服务部 | 抗人乳头瘤病毒16 e6 t细胞受体 |
| US20160333422A1 (en) | 2014-01-24 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors |
| DK3149031T3 (da) | 2014-05-29 | 2020-03-16 | Us Health | Anti-human papillomavirus 16 e7 t-cellereceptorer |
| US10973894B2 (en) | 2014-10-02 | 2021-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation |
| CN107074932A (zh) | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法 |
| JPWO2016067968A1 (ja) * | 2014-10-29 | 2017-04-27 | 昭和電工株式会社 | ミトコンドリア機能改善剤 |
| GB201519340D0 (en) | 2015-11-02 | 2015-12-16 | Cambridge Entpr Ltd | Methods of T-lymphocyte expansion |
| WO2018053233A1 (en) | 2016-09-15 | 2018-03-22 | Memorial Sloan Kettering Cancer Center | Inhibition of acetyl-coa metabolism for treatment and prevention of immune system diseases and disorders |
-
2019
- 2019-04-22 CN CN201980037634.5A patent/CN112262212B/zh active Active
- 2019-04-22 WO PCT/US2019/028513 patent/WO2019209715A1/en not_active Ceased
- 2019-04-22 CA CA3097858A patent/CA3097858A1/en active Pending
- 2019-04-22 CN CN202410809055.0A patent/CN118726256A/zh active Pending
- 2019-04-22 AU AU2019260656A patent/AU2019260656B2/en active Active
- 2019-04-22 EP EP19726230.6A patent/EP3784774B1/en active Active
- 2019-04-22 JP JP2020559481A patent/JP7342030B2/ja active Active
- 2019-04-22 US US17/050,045 patent/US12415845B2/en active Active
-
2025
- 2025-08-18 US US19/302,338 patent/US20260042814A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nallasamy et al. | Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis | |
| Nojima et al. | In-vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo | |
| JP6022667B2 (ja) | 炎症性ヒトＴｈ１７細胞の増殖および機能を決定的に調節するＩＣＯＳ | |
| US20210085719A1 (en) | Bispecific car t-cells for solid tumor targeting | |
| Terabe et al. | Role of IL-13 in regulation of anti-tumor immunity and tumor growth | |
| CN103756964B (zh) | 一种高效扩增cd3-cd56+的自然杀伤细胞培养系统的方法 | |
| TW202020141A (zh) | 一種用於nk細胞體外擴增的培養基體系及nk細胞體外擴增的方法 | |
| WO2020057486A1 (zh) | 经修饰的t细胞、其制备方法及用途 | |
| IL274293B2 (en) | Process for generating therapeutic compositions of engineered cells | |
| JP2017533706A5 (enExample) | ||
| JP2020534839A5 (enExample) | ||
| CN109121413A (zh) | 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法 | |
| JP2012521215A5 (enExample) | ||
| JP2016524914A5 (enExample) | ||
| Lv et al. | γδT cells, a key subset of T cell for cancer immunotherapy | |
| WO2019206326A1 (zh) | 改进的t细胞治疗方法 | |
| Huang et al. | T cell immune response within B-cell follicles | |
| CN101313061A (zh) | 扩增双阴性t细胞的方法 | |
| Fu et al. | Efficacy of human iPSC-derived CAR-NK cells targeting multiple myeloma cells | |
| Xiao et al. | Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity | |
| Koppers et al. | Chimeric antigen receptor-macrophages: Emerging next-generation cell therapy for brain cancer | |
| Lin et al. | Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy | |
| CN112262212B (zh) | 使用羟基柠檬酸和/或其盐产生t细胞群体的方法 | |
| Amiji et al. | Cancer Immunology and Immunotherapy: Volume 1 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy | |
| Eardley et al. | Suppressor T-Cells are not Easily Cloned by Methods for Cloning Helper T-Cells |